CEO of InSilico Medicine & Deep Longevity. CSO of Biogerontology Research Foundation.
Dr. Zhavoronkov holds two bachelor degrees from Queen’s University, a master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University.
As at Sept-20: 313 Publications, 4,053 Citations
Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and diversity.AI initiative.
Author of "The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy", Palgrave Macmillan, NY, 2013 - available in English, Japanese, Chinese, and Polish.
Visit website: http://www.agelessbook.com/the-author-details/
See also: Insilico Medicine - Biotechnology company that uses artificial intelligence to develop new drugs and for aging research
Alex Zhavoronkov is also referenced in the following:
Latest progress in the molecular, cellular and organismal basis of aging
Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.
NUS Healthy Longevity webinar with Alex Zhavoronkov - CEO of Insilico Medicine
AMA with Sergey Young, Alex Zhavoronkov and Sourav Sinha
Workshop is part of ARDD 2021 conference that brings health care providers involved in longevity, organized by Cassandra Coburn and Evelyne Bischof. (FREE)
The Kitalys institute virtual conference targeting key questions that will impact the future of aging and extending healthspan
Alex Zhavoronkov Creations
Alex Zhavoronkov News
Deep Longevity's epigenetic aging clock, DeepMAge, retrained to use saliva samples
Longevity Technology - 02-Aug-2021
With an accuracy of 4.7 years it is much more convenient for home testingRead more...
Insilico raises $255M to advance human trials and AI drug discovery platform
Longevity Technology - 22-Jun-2021
New collab with Teva Pharmaceuticals to identify drug targets for various diseasesRead more...
First-ever AI designed drug candidate for pulmonary fibrosis
Longevity Technology - 24-Feb-2021
Insilico's novel drug target is prepping for IND studies, expecting to start clinical studies by early 2022Read more...
Super summary of 3rd Annual Longevity Therapeutics Summit
Lifespan.io (LEAF) - 16-Feb-2021
More and more companies making greater and greater progress - 2021 could be an exciting yearRead more...
AI based aging clock predicts psychological age
Longevity Technology - 16-Dec-2020
Deep longevity's psychological clock might help you feel younger and live longerRead more...
Pharma company teams with AI to develop anti aging solutions
Longevity Technology - 15-Oct-2020
Taisho and Insilico collabs to identify novel targets for senolytic drugsRead more...
Alex Zhavoronkov explains why AI can help in peer reviewing drug development research
Nature Biotechnology - 14-Sep-2020
An automated sense-check of publications sounds like a good ideaRead more...
New app helps identify biological age and methods to slow it down
Fortune - 17-Aug-2020
Apps such as Young. ai will play a key role in helping understand and reversing aging processesRead more...
AI reduces drug discovery from years to days - and that's just the start
Singularity Hub - 23-Jul-2020
Insilico Medicine is slashing the cost of drug developmentRead more...
Deep Longevity investors bet on growing need for aging and longevity biomarkers
FierceBiotech - 15-Jul-2020
Biological clocks are a moving target so they'll need other researchers to corroborate their analysisRead more...
Should WHO use a new framework for the diagnosis and treatment of age-related diseases?
Lifespan.io (LEAF) - 08-May-2020
LEAF summarises and exchange of thoughts between leading aging researchersRead more...
Proposed strategy to protect elderly from gerolavic infections like COVID-19
Forbes - 31-Mar-2020
To benefit long term global health and longevity, and enhance economic recoveryRead more...
Nanalyze looks at Insilico Medicine's AlphaGo moment in pharma
Nanalyze - 09-Oct-2019
From lab to clinic in 2 years instead of 10 would have a huge impact on healthRead more...
Insilico and ARK enter a research collaboration on health-span and longevity
EurekAlert! - 22-May-2019
AI-based methods, to explore mechanisms of ageing and improving health-spanRead more...
Gut microbiome predicts age with 4 year accuracy
Lifespan.io (LEAF) - 15-Jan-2019
It both affects and is affected by its host statusRead more...
Aging focused biotechs forms AI based joint venture
FierceBiotech - 14-Aug-2018
Groundbreaking research biotechs performs aging research together for longevityRead more...
AgeX Identifies Genes Implicated in Regeneration and Cancer
Business Wire - 02-Jan-2018
Study that reveals genes implicated in tissue regeneration, cancer, and aging. Worked in collabo...Read more...
AI-powered application to assess visual aging biomarkers in lab animals
Lifespan.io (LEAF) - 29-Aug-2017
Lifespan.io is launching a crowdfunding campaign to support MouseAGE. Software will assess visua...Read more...
British billionaire gambles on an anti-aging upstart
Endpoints News - 26-Jul-2017
We are at an inflection point for the treatment of aging. We can generate molecules with specifi...Read more...
AI Versus Aging
Lifespan.io (LEAF) - 18-Apr-2017
Interview with Dr. Alex Zhavoronkov, CEO of Insilico Medicine Company awarded the ‘Most Promisin...Read more...
Display all news
Articles written by Alex Zhavoronkov
Artificial intelligence can revolutionise longevity medicine
Nature Aging - 14-Jan-2021
Collaboration among stakeholders can transform public health into public health longevityRead more...